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Background: Obstructive lung disease (OLD) is frequently unrecognized and undertreated. 
Urban drug users are at higher risk for OLD due to race, behavioral, and socioeconomic char-
acteristics, yet little data exist on prevalence and risk factors associated with unrecognized OLD 
in this population.
Objective: The objective of this study is to determine the prevalence of unrecognized OLD 
in an urban population and identify the characteristics associated with lack of physician- 
diagnosed OLD.
Design: Cross-sectional analysis from the Acquired Immunodeficiency Syndrome Linked to the 
Intravenous Experience (ALIVE) study, an observational study of current and former injection 
drug users in Baltimore, Maryland, USA.
Participants: All participants with spirometry-defined airflow obstruction were stratified by 
the presence or absence of physician diagnosis of OLD.
Main measures: Using cross-sectional demographic, clinical, and spirometric measurements, 
multivariable regression models were generated to identify factors independently associated 
with unrecognized OLD.
Key results: Of the 1083 participants evaluated in the ALIVE lung substudy, 176 (16.3%) met 
spirometric criteria for OLD. Of those, only 88 (50%) had a physician diagnosis of OLD. 
The prevalence of unrecognized OLD decreased as severity of airflow obstruction increased. 
Factors independently associated with unrecognized OLD were absence of respiratory symptoms 
(prevalence ratio [PR], 1.70; 95% confidence interval [CI]: 1.29–2.23; P , 0.01) and less severe 
dyspnea (PR, 0.83; 95% CI: 0.72–0.96, per point increase in dyspnea scale; P = 0.01). In the 
subset of human immunodeficiency virus (HIV)–infected participants, the use of antiretroviral 
therapy (ART) was independently associated with an increased prevalence of unrecognized 
OLD (PR, 1.93; 95% CI: 1.05–3.56; P = 0.03).
Conclusions: In a cohort of current and former urban drug users, OLD is substantially under-
recognized and associated with lack of respiratory symptoms. Relying on the presence of 
respiratory symptoms as a trigger to perform spirometry may result in a substantial underdiag-
nosis of OLD in this population. HIV-infected individuals receiving ART are a population 
particularly vulnerable to unrecognized OLD.
Keywords: obstructive lung disease, human immunodeficiency virus infection, COPD, asthma, 
spirometry
Introduction
Obstructive lung diseases (OLDs), specifically asthma and chronic obstructive pulmo-
nary disease (COPD), are prevalent conditions associated with substantial morbidity 
and mortality in the United States.1–3 OLD is frequently unrecognized even in smokers.4–6 International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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Several studies have identified populations at higher risk for 
unrecognized OLD including rural populations,7 the urban 
homeless,8 and medical inpatients.9,10 Urban populations with 
a history of current or former drug use represent a poorly 
studied group with a substantial burden of tobacco abuse and 
lower socioeconomic status.11–13 There is an increased risk 
of human immunodeficiency virus (HIV) infection in the 
urban population,14,15 and HIV is associated with an increased 
prevalence of OLD.16–18 Each of these factors markedly 
increases the susceptibility of this population to OLD.19–21 
Characterizing the prevalence of unrecognized OLD is rel-
evant given that unrecognized OLD is often undertreated.8,22 
It remains unclear what patient characteristics may be asso-
ciated with unrecognized OLD, especially in high-risk 
populations.
The AIDS Linked to the Intravenous Experience (ALIVE) 
study has prospectively observed a cohort of intravenous 
drug users (IDUs) in Baltimore, Maryland, USA since 1988.23 
This population has been previously recognized to have 
limited access and delayed care for HIV .24 We have described 
the substantial prevalence of respiratory symptoms in this 
population previously.25 Moreover, the heavy burden of smok-
ing dependence in this cohort makes it an ideal population 
to examine issues related to undiagnosed OLD. Clinical and 
spirometric data have been collected on this cohort allowing 
for the determination of unrecognized OLD. In the current 
study, we use the cross-sectional data from the ALIVE study 
to determine the prevalence of unrecognized OLD in a large 
group of urban IDUs. We determine demographic and clini-
cal factors associated with unrecognized OLD in this 
population.
Methods
setting and participants
The methods for recruitment and data collection in the ALIVE 
study have been described previously.23 Briefly, ALIVE 
participants were recruited if they were aged $18 years, living 
in inner-city Baltimore, Maryland, and injecting drugs at 
enrollment. As part of a lung disease substudy, ALIVE par-
ticipants completed an extensive respiratory questionnaire 
and performed spirometry testing at a regularly scheduled 
ALIVE biannual visit. Cross-sectional demographic and 
clinical data collected at the time of the lung substudy evalu-
ation (January 9, 2007–June 26, 2009) were included in this 
analysis. This study was approved by Institutional Review 
Board of the Johns Hopkins Bloomberg School of Public 
Health and Johns Hopkins University School of Medicine 
(Protocol NA_00020295). All participants provided written 
informed consent.
For this analysis, all individuals with spirometry-defined 
obstruction (as defined below) were selected. An individual 
was defined as having recognized OLD if spirometric 
obstruction was present and the individual reported a physi-
cian diagnosis of asthma, chronic bronchitis, or emphysema. 
An individual was defined as having unrecognized OLD if 
spirometric obstruction was present and the individual 
reported no physician diagnosis of asthma, chronic   bronchitis, 
or emphysema.
Measurements
Participants completed a modified version of the American 
Thoracic Society respiratory questionnaire.26 The question-
naire collected information regarding presence, frequency 
and timing of respiratory symptoms (cough, phlegm, and 
wheezing), and dyspnea. Absence of respiratory symptoms 
was defined as answering in the negative to usually having 
cough, usually bringing up phlegm, and ever wheezing. 
Dyspnea was assessed using the modified Medical Research 
Council (MRC) questionnaire with a validated 0–4 scale, 
with a higher score indicating worse dyspnea.27,28 Smoking 
status and duration, injection drug use in the last 6 months, 
and antiretroviral use were determined by self-report. 
  Participants were asked if they had ever received a physician 
diagnosis of asthma, chronic bronchitis, or emphysema.
OLD was defined as a prebronchodilator ratio of forced 
expiratory volume in one second (FEV1) with forced vital 
capacity (FVC) of ,0.70. Severity of spirometric obstruction 
was defined by using the Global Initiative for Obstructive 
Lung Disease criteria: mild (FEV1 $ 80% predicted), moder-
ate (FEV1 = 50%–79% predicted), severe (FEV1 = 30%–49% 
predicted), and very severe (FEV1 , 30% predicted).1 Percent 
predicted values and lower limit of normal (LLN) criteria 
were calculated using standard formulas.29 Spirometry was 
performed using a KOKO® (Pulmonary Data Services, Inc, 
Louisville, CO) pneumotach in accordance with American 
Thoracic Society guidelines.30
statistical analysis
Clinical and demographic characteristics between groups 
were presented as mean (standard deviation), median (inter-
quartile range [IQR]), or n (%). Continuous variables were 
compared using t-test for normally distributed data and 
Wilcoxon–Mann–Whitney test for skewed data. Categorical 
variables were compared with Pearson’s  2 test. Because odds International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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ratios can overestimate the magnitude of association between 
covariates and the outcome of interest in cross-sectional 
studies when the prevalence of the outcome exceeds 20%,31–33 
univariate and adjusted prevalence ratios (PR) with 95% 
confidence intervals (95% CI) were generated using Poisson 
regression models with robust variance.34,35 Covariates were 
evaluated based upon biological plausibility and inspection 
of exploratory data analyses. Prevalence of unrecognized 
obstruction stratified by disease severity was compared using 
Pearson’s  2 test. Stata software (version 10.0; Stata Corp, 
College Station, TX) was used for statistical analysis.
Results
Prevalence and correlates  
of unrecognized OLD
Of the 1083 participants evaluated in the ALIVE lung 
  substudy, 176 (16.3%) participants met criteria for spiromet-
ric obstruction. Only 88 (50%) participants with OLD had a 
physician diagnosis of OLD. Among participants with rec-
ognized OLD, 51 (58%) had a physician diagnosis of asthma 
only, 13 (15%) COPD only, and 24 (27%) reported both 
asthma and COPD. As a comparison, of the 907 participants 
with normal pulmonary function, 213 (23%) reported a 
physician diagnosis of OLD. Of these, 120 (56%) had a 
physician diagnosis of asthma only, 60 (28%) COPD only, 
and 33 (16%) reported both asthma and COPD. The mean 
age of participants with spirometric obstruction was 50 years, 
nearly 70% were male and 85% were black (Table 1). A total 
of 155 (88%) participants were current smokers with a 
median pack-years of 22. Approximately 40% reported 
injection drug use in the previous 6 months. Nearly 30% 
were HIV-positive, with a median CD4 count of 331 cells/mm3. 
Of HIV-infected subjects, 51% had been using antiretrovirals 
in the last 6 months. The prevalence of OLD did not differ 
by HIV status (16.5% HIV-infected vs 16.2% HIV-uninfected 
individuals; P = 0.89) or current injection drug use sta-
tus (15.7% current users vs 16.6% prior users; P = 0.70). 
Participants with unrecognized OLD were more frequently 
male when compared to those with recognized OLD (80% 
vs 55%; P , 0.01). The prevalence of unrecognized OLD 
did not differ by pack-years smoking history. Aside from 
gender, demographic and clinical characteristics were similar 
between those with recognized and unrecognized OLD.
Respiratory symptoms were common in the cohort, 
with 74% reporting cough, wheeze, or phlegm (Table 2). 
  Respiratory symptoms were less frequent in individuals with 
unrecognized OLD. A total of 50 (57%) participants with 
unrecognized OLD reported any respiratory symptoms 
compared with 81 (92%) participants with recognized OLD 
(P , 0.01). The frequencies of individual symptoms of 
cough, wheeze, and phlegm were all lower in individuals 
with unrecognized OLD. Less severe dyspnea, represented 
by lower MRC scores, was present in participants with 
  unrecognized OLD.
Table 1 Demographic and clinical characteristics of study participants
Overall Recognized OLD Unrecognized OLD P valuea
n 176 88 88
Age (years) 49.6 (8.9) 49.9 (8.47) 49.4 (9.31) 0.74
Male, n (%) 118 (67.1) 48 (54.6) 70 (79.6) ,0.01
Black race/ethnicity, n (%) 149 (84.7) 74 (84.1) 75 (85.2) 0.83
BMI (kg/m2) 23.9 (21.5–28.1) 23.8 (21.5–28.8) 24.1 (21.6–28.0) 0.77
Completed high school education, n (%) 68 (38.6) 36 (40.9) 32 (36.4) 0.54
smoking status, n (%)
  Current 155 (88.1) 78 (88.6) 77 (87.5)
  Former 15 (8.5) 7 (8.0) 8 (9.1)
  never 6 (3.4) 3 (3.4) 3 (3.4) 0.96
smoking, pack-years 22 (14–39) 23.5 (13.5–41.0) 21.5 (14.5–38.0) 0.69
IDU, n (%)b 71 (40.3) 37 (42.1) 34 (38.6) 0.65
hIV-infected, n (%) 51 (29.0) 28 (31.8) 23 (26.2) 0.41
CD4 count (cells/mm3)c 331 (168–491) 298 (174–489) 380 (161–574) 0.56
Viral load undetectable, n (%)c 25 (49.0) 13 (46.4) 12 (52.2) 0.68
Viral load (log10)d 4.23 (3.18–5.33) 2.85 (2.60–4.42) 2.60 (2.60–4.02) 0.60
Antiretroviral use, n (%)b 26 (51.0) 11 (39.9) 15 (65.2) 0.07
Notes: aP value comparing recognized to unrecognized OLD categories; bIn prior 6 months; cMean (sD) or n (%) of hIV-infected participants only; dAmong hIV-infected 
individuals with detectable viral load.
Abbreviations: OLD, obstructive lung disease; BMI, body mass index; IDU, injection drug use; HIV, human immunodeficiency virus.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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effect of disease severity on OLD 
recognition
The median FEV1/FVC ratio of the study sample was 0.65 
(IQR: 0.60–0.68) with a mean FEV1% predicted of 71.7% ± 
18.8%. Overall, 65 (37%) had mild obstruction, 90 (51%) 
had moderate obstruction, 17 (10%) had severe obstruction, 
and 4 (2%) had very severe obstruction. The mean FEV1% 
predicted was higher in participants with unrecognized OLD 
when compared to recognized OLD (77.9 ± 19 vs 65.5 ± 20; 
P = 0.04). To determine if the prevalence of unrecognized 
OLD differed by categories of disease severity, the 176 par-
ticipants were stratified by FEV1 into four groups: mild 
(n = 65), moderate (n = 90), severe (n = 17), and very severe 
(n = 4). The prevalence of unrecognized OLD decreased as 
severity of airflow obstruction increased (Figure 1). Of the 
65 subjects with mild OLD, 44 (68%) had unrecognized 
OLD, whereas 40 (44%) of the 90 participants with moderate 
obstruction were unrecognized. Of the 17 subjects with 
severe obstruction, 4 (24%) were unrecognized. None of the 
subjects with very severe obstruction were unrecognized.
Factors independently associated  
with unrecognized OLD
Univariate and multivariate Poisson regression analyses were 
performed to explore relationships between demographic and 
clinical factors and unrecognized OLD (Table 3). After account-
ing for relevant demographic and clinical characteristics, lack 
of respiratory symptoms and milder dyspnea were indepen-
dently associated with an increase in the prevalence of unrec-
ognized OLD. The absence of any respiratory symptoms was 
independently associated with a 70% increase in the prevalence 
of unrecognized OLD (PR, 1.70; 95% CI: 1.29–2.23; P , 0.01). 
Each point increase in the MRC score (indicating worse dys-
pnea) was associated with ∼20% reduction in the prevalence 
of unrecognized OLD (PR, 0.83; 95% CI: 0.72–0.96; P = 0.01). 
These findings persisted after adjusting for HIV infection, cur-
rent employment, and high school education.
To explore the potential association between treatment for 
HIV and recognition of OLD, the subset of 51 HIV-  infected 
individuals with OLD were analyzed separately. After adjust-
ing for baseline characteristics, respiratory symptoms, and 
MRC scores in this subset, the use of ART in the last 6 months 
was associated with an increased prevalence of unrecognized 
OLD (PR, 1.94; 95% CI: 1.05–3.56; P = 0.03). This 
Table 2 respiratory symptoms and dyspnea measures of study participants
Overall Recognized OLD Unrecognized OLD P valuea
n 176 88 88
respiratory symptoms
  Anyb 131 (74.4) 81 (92.1) 50 (56.8) ,0.01
  Usually have cough 82 (46.6) 53 (60.2) 29 (33.0) ,0.01
  ever wheeze 105 (59.7) 72 (81.8) 33 (37.5) ,0.01
  Usually have phlegm 85 (48.2) 55 (62.5) 30 (34.1) ,0.01
MrC score
 0 108 (61.4) 41 (46.6) 67 (76.1)
 1 14 (8.0) 6 (6.8) 8 (9.1)
 2 10 (5.7) 7 (8.0) 3 (3.4)
 3 19 (10.8) 12 (13.6) 7 (8.0)
 4 25 (14.2) 22 (25.0) 3 (3.4) ,0.01
Notes: aP value comparing recognized to unrecognized OLD categories; bAny respiratory symptoms include any report of usually having cough, usually bring up phlegm, or 
ever wheezing.
Abbreviations: OLD, obstructive lung disease; MrC, Medical research Council.
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Figure 1 Prevalence of unrecognized OLD based on severity of airway obstruction. 
The 176 subjects were stratified by FEV1 into four groups: mild ($80% predicted; 
n  =  65),  moderate  (50%–79%  predicted;  n  =  90),  severe  (30%–49%  predicted; 
n = 17), and very severe (,30% predicted; n = 4). height of bar and data labels 
represents proportion of subjects in that stratum of OLD severity.
Abbreviations: FeV1, forced expiratory volume in the one second; OLD, obstructive 
lung disease.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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association was attenuated when incorporating %   predicted 
FEV1 into the adjusted model (PR, 1.79; 95% CI: 0.99–3.26; 
P = 0.055).
Discussion
In this study of OLD in an urban cohort of former and cur-
rent IDUs, we have found that the prevalence of unrecog-
nized OLD is very high, with half of participants with 
spirometric obstruction lacking a physician diagnosis. The 
prevalence of unrecognized OLD was highest among 
  participants with milder degrees of airway obstruction. 
Lack of respiratory symptoms and less severe dyspnea 
were independently associated with unrecognized OLD 
in this population after accounting for severity of airway 
obstruction. The use of antiretroviral therapy (ART) in 
HIV-infected participants was associated with an increased 
prevalence of unrecognized OLD.
Our observation of a substantial underrecognition of OLD 
in this cohort identifies the urban IDU population as a group 
particularly susceptible to undiagnosed OLD. We observed 
a 50% prevalence of unrecognized OLD, higher than that 
observed in rural, medical inpatient, and Spanish community-
based populations.7,9,36 Based on our findings, prevalence 
estimates of disease burden from OLD are likely to be 
  significantly underestimated in the urban IDU population.
Because use of a fixed ratio to define OLD may result in 
overdiagnosis of disease in a younger population, we also 
evaluated this cohort using a LLN criteria29 to define OLD. 
Although an additional nine participants were defined as hav-
ing OLD using LLN criteria, the prevalence of   unrecognized 
OLD did not differ (50%).
Several reasons may exist for the high prevalence of 
unrecognized OLD in this population. Urban populations 
may have fewer primary health care encounters,37 the time 
at which spirometric testing is most likely to occur.38,39 
  Primary care providers who care for such individuals may 
attend to more overt symptoms and diseases at a particular 
health care encounter, thereby leaving OLD unrecognized.40 
Our observation that ART use is associated with a higher 
prevalence of unrecognized OLD in HIV-infected partici-
pants suggests that physicians may focus on HIV-related 
illnesses, deferring non-HIV-related diagnoses such as OLD 
for subsequent encounters. Alternatively, individuals with 
more severe OLD (and therefore more frequently recognized 
OLD) may represent a cohort less likely to access HIV care. 
The prevalence of unrecognized OLD is similar to that 
observed in an analysis of the general population.41 However, 
unlike the general population, the urban population is 
exposed to increased risk factors for OLD and the difficulty 
in access to care. Therefore, aggressive spirometric screening 
programs for at-risk individuals may allow for earlier detec-
tion and subsequent lifestyle modification and treatment of 
OLD in the urban population.
In our analysis, lack of symptoms was a strong indepen-
dent factor associated with unrecognized OLD. Several 
studies have explored the long-term outcomes of individuals 
with asymptomatic OLD, reaching conflicting results. 
Bridevaux and colleagues demonstrated that individuals with 
mild COPD who lack respiratory symptoms have long-term 
decline in FEV1 and health care utilization similar to   symptom- 
free individuals without OLD.42 However, in a young 
  community-based cohort, Mannino and colleagues have 
shown that individuals with symptom-free moderate OLD 
have a 60% increase in the risk of death (hazard ratio [HR], 
1.6; 95% CI: 1.3–2.1) when compared to healthy   individuals.43 
The risk of death in moderate COPD further increases when 
symptoms are present (HR, 2.1; 95% CI: 1.7–2.6). These 
data suggest that the one-quarter of our participants with 
Table 3 Factors associated with unrecognized obstructive lung disease (n = 176)
Predictors Unadjusted prevalence  
ratio (95% CI)
P value Adjusted prevalence  
ratioa (95% CI)
P value
Age (per 10 years) 0.98 (0.82–1.15) 0.73 0.88 (0.74–1.08) 0.24
Male gender 1.91 (1.26–2.89) ,0.01 1.47 (0.97–2.22) 0.07
race (black vs nonblack) 1.05 (0.68–1.60) 0.84 1.34 (0.90–2.00) 0.15
high school education 0.91 (0.66–1.24) 0.54 0.85 (0.64–1.12) 0.25
Pack-years (per 10 pack-years)b 0.96 (0.88–1.04) 0.33 1.00 (0.92–1.09) 0.94
hIV infection 0.87 (0.61–1.23) 0.42 0.88 (0.64–1.20) 0.42
FeV1 (per 10% predicted) 1.21 (1.11–1.32) ,0.01 1.07 (0.97–1.18) 0.15
no respiratory symptoms 2.21 (1.72–2.85) ,0.01 1.70 (1.29–2.23) ,0.01
MrC score (per point increase) 0.74 (0.64–0.86) ,0.01 0.83 (0.72–0.96) 0.01
Notes: aPrevalence ratio adjusted for other predictors in table; bPack-years calculated as number of packs per day × number of years smoking.
Abbreviations: hIV, human immunodeficiency virus; FEV1, forced expiratory volume in the one second; MrC, Medical research Council.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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unrecognized moderate OLD represent a group at increased 
risk of death, regardless of the presence of symptoms. 
  Relying strictly on presence of respiratory symptoms as a 
trigger to perform spirometry in at-risk individuals may 
result in a substantial underdiagnosis of OLD and a missed 
opportunity to intervene with smoking cessation programs 
and pharmacological treatments in a group with increased 
  mortality. Tobacco use has been shown to be a distal predictor 
of mortality among long-term narcotic addicts.44,45 Studies 
suggest that awareness of airflow obstruction among smokers 
enhances smoking cessation rates.46,47 Thus, decreasing the 
prevalence of unrecognized OLD may enhance smoking 
cessation and survival in this population.
Although the presence of OLD does not mandate phar-
macological interventions, especially in the case of mild 
disease with few symptoms, lifestyle modifications to prevent 
progression of disease are of benefit.1 Although current data 
do not suggest that inhaled pharmacotherapies substantially 
alter the decline of FEV1 or mortality, these agents are effec-
tive at controlling symptoms and exacerbations associated 
with OLD.1 Given the substantial proportion of partici-
pants with unrecognized OLD reporting symptoms of cough, 
wheeze, or phlegm, there exists a potential improvement in 
quality of life with making the diagnosis and treatment of 
OLD in an urban population of IDUs.
Our study has some limitations. We do not have data on 
pre- and postbronchodilator reversibility to allow for distinc-
tion between reversible and fixed airways obstruction. 
However, the use of consistent, standardized spirometry 
measurements allows us to make valid classification of the 
presence of OLD. Additionally, we did not collect data on 
other lung diseases (eg, bronchiectasis) which may impact 
the diagnosis of OLD. Although our findings are valid for 
an urban population of IDUs, they may not be generalizable 
to the urban population at large or other communities. 
Despite these limitations, the standardized and extensive 
data collection used for this analysis allows us to make valid 
conclusions regarding unrecognized OLD in a high-risk 
population.
In summary, we have observed a high prevalence of 
unrecognized OLD in an urban population of former and 
current IDUs. Lack of respiratory symptoms and milder 
dyspnea were independently associated with unrecognized 
OLD. HIV-  infected individuals receiving ART are a popula-
tion particularly vulnerable to unrecognized OLD. These 
findings emphasize the marked underrecognition of a chronic 
yet treatable condition in a particularly vulnerable   population. 
  Individual   practitioners and health care policy groups should 
use this information to help develop OLD detection, 
  prevention, and treatment strategies for individuals in urban 
centers.
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